iTeos Therapeutics and GlaxoSmithKline plc entered an agreement to co-develop and co-commercialize EOS-448, an anti-TIGIT monoclonal antibody currently in phase I development as a potential treatment for cancer. TIGIT, part of the CD226 checkpoint axis, has demonstrated potential as a promising target for the next generation of immuno-oncology therapies based on preclinical data and a phase II randomized clinical trial. With this collaboration has access to antibodies that synergistically target...